Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Checking In On ARCA Biopharma

On March 20, 2014, ARCA Biopharma (NASDAQ:ABIO) filed its Form 10-K annual report for the period ending December 31, 2013, providing investors an update on the financial position and business prospects for the company. A quick look at the financials and we see that ARCA reported no revenues in 2013, as expected, and a net loss of $9.0 million, or $1.04 per share. Net cash usage from operating and investing activities in 2013 totaled $5.3 million, with $1.9 million coming in the fourth quarter 2013. ARCA funded operations in 2013 through $19.2 million in financing activities, driven primarily by a $20 million public offering that took place in June 2013.

ARCA exited 2013 with $16.8 million in cash

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details